This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Muir, A. H Articles by Belch, J. J. Search for Related Content PubMed PubMed Citation Articles by Muir, A. H Articles by Belch, J. J. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Herbal Medicine Raynaud's Disease Social Bookmarking                         What's this?

The use of Ginkgo biloba in Raynaud’s disease: a double-blind placebo-controlled trial

Peripheral Vascular Diseases Research Unit, University Department of Medicine, Ninewells Hospital & Medical School, Dundee, UK, a.h.muir{at}dundee.ac.uk

Rosalind Robb

Peripheral Vascular Diseases Research Unit, University Department of Medicine, Ninewells Hospital & Medical School, Dundee, UK

Margaret McLaren

Peripheral Vascular Diseases Research Unit, University Department of Medicine, Ninewells Hospital & Medical School, Dundee, UK

Fergus Daly

Peripheral Vascular Diseases Research Unit, University Department of Medicine, Ninewells Hospital & Medical School, Dundee, UK

Jill JF Belch

Peripheral Vascular Diseases Research Unit, University Department of Medicine, Ninewells Hospital & Medical School, Dundee, UK

Raynaud’s phenomenon (RP) is a common and painful condition characterized by episodic digital ischaemia produced by emotion and cold. Treatment of RP is notoriously difficult because of the high incidence of side effects. The aim of our study was to investigate the clinical efficacy of a standardized Ginkgo biloba extract (Seredrin) in the treatment of RP in patients with no apparent, associated condition such as systemic sclerosis.

A two-week assessment period was done during which patients were asked to record frequency, severity and duration of attacks in diaries. Subjects were then randomized independently of the study centre to receive either active or placebo treatment for 10 weeks, during which time the same data were recorded in their diaries. Patients were seen after two and four weeks of treatment and at the end of the 10-week treatment phase. Blood samples pre- and post-treatment were taken for haemorrheology.

Only in the number of attacks per day was there a significant effect of treatment over placebo. The number of attacks per week prior to treatment with Seredrin was 13.2 6 16.5 reducing to 5.8 6 8.3, a reduction of 56%, whereas placebo reduced the number by only 27% (p < 0.00001). There were no significant differences in haemorrheology between the two groups.

Ginkgo biloba phytosome may be effective in reducing the number of Raynaud’s attacks per week in patients suffering from Raynaud’s disease.

Key Words: alternative medicine • Ginkgo biloba • Raynaud’s disease

Vascular Medicine, Vol. 7, No. 4, 265-267 (2002)
DOI: 10.1191/1358863x02vm455oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Malenfant, M. Catton, and J. E. Pope The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis Rheumatology, July 1, 2009; 48(7): 791 - 795. [Abstract] [Full Text] [PDF]

				H.-C. Ou, W.-J. Lee, I-T. Lee, T.-H. Chiu, K.-L. Tsai, C.-Y. Lin, and W. H.-H. Sheu Ginkgo biloba extract attenuates oxLDL-induced oxidative functional damages in endothelial cells J Appl Physiol, May 1, 2009; 106(5): 1674 - 1685. [Abstract] [Full Text] [PDF]